FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA approved cell-based gene therapy for the treatment of adult patients with relapsed or refractory multiple myeloma

Listen to a soundcast of the March 26, 2021 FDA approval of ABECMA (idacabtagene vicleucel) the first cell-based gene therapy for treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.

Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news